JP2015071598A5 - - Google Patents

Download PDF

Info

Publication number
JP2015071598A5
JP2015071598A5 JP2014205331A JP2014205331A JP2015071598A5 JP 2015071598 A5 JP2015071598 A5 JP 2015071598A5 JP 2014205331 A JP2014205331 A JP 2014205331A JP 2014205331 A JP2014205331 A JP 2014205331A JP 2015071598 A5 JP2015071598 A5 JP 2015071598A5
Authority
JP
Japan
Prior art keywords
antigen
antibody
vaccine
antigen complex
gag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014205331A
Other languages
English (en)
Japanese (ja)
Other versions
JP6109800B2 (ja
JP2015071598A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015071598A publication Critical patent/JP2015071598A/ja
Publication of JP2015071598A5 publication Critical patent/JP2015071598A5/ja
Application granted granted Critical
Publication of JP6109800B2 publication Critical patent/JP6109800B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014205331A 2008-07-16 2014-10-06 最大限のｇａｇ及びｎｅｆを樹状細胞に対して標的化することに基づくｈｉｖワクチン Expired - Fee Related JP6109800B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8123408P 2008-07-16 2008-07-16
US61/081,234 2008-07-16

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011518925A Division JP5984388B2 (ja) 2008-07-16 2009-07-16 最大限のｇａｇ及びｎｅｆを樹状細胞に対して標的化することに基づくｈｉｖワクチン

Publications (3)

Publication Number Publication Date
JP2015071598A JP2015071598A (ja) 2015-04-16
JP2015071598A5 true JP2015071598A5 (https=) 2015-05-28
JP6109800B2 JP6109800B2 (ja) 2017-04-05

Family

ID=41551022

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011518925A Expired - Fee Related JP5984388B2 (ja) 2008-07-16 2009-07-16 最大限のｇａｇ及びｎｅｆを樹状細胞に対して標的化することに基づくｈｉｖワクチン
JP2014205331A Expired - Fee Related JP6109800B2 (ja) 2008-07-16 2014-10-06 最大限のｇａｇ及びｎｅｆを樹状細胞に対して標的化することに基づくｈｉｖワクチン

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011518925A Expired - Fee Related JP5984388B2 (ja) 2008-07-16 2009-07-16 最大限のｇａｇ及びｎｅｆを樹状細胞に対して標的化することに基づくｈｉｖワクチン

Country Status (19)

Country Link
US (1) US9109011B2 (https=)
EP (3) EP2966091B1 (https=)
JP (2) JP5984388B2 (https=)
KR (2) KR20110036618A (https=)
CN (1) CN102625714B (https=)
AP (1) AP2011005541A0 (https=)
AU (1) AU2009270771B2 (https=)
BR (1) BRPI0915915A2 (https=)
CA (1) CA2730742C (https=)
DK (1) DK2966091T3 (https=)
ES (2) ES2890230T3 (https=)
IL (1) IL210646A0 (https=)
MX (1) MX2011000507A (https=)
MY (1) MY155377A (https=)
NZ (3) NZ590628A (https=)
PT (1) PT2966091T (https=)
RU (2) RU2539765C2 (https=)
WO (1) WO2010009346A2 (https=)
ZA (1) ZA201100398B (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010222928B2 (en) 2008-07-16 2012-11-29 Baylor Research Institute Antigen presenting cell targeted vaccines
CA2730742C (en) 2008-07-16 2017-05-23 Baylor Research Institute Hiv vaccine based on targeting maximized gag and nef to dendritic cells
CN102170908A (zh) * 2008-08-29 2011-08-31 莱顿大学医学中心附属莱顿教学医院 向个体的肿瘤引流淋巴结递送cd40激动剂
EP2406289B1 (en) * 2009-03-10 2017-02-22 Baylor Research Institute Antigen presenting cell targeted anti-viral vaccines
DK2406286T3 (en) 2009-03-10 2016-08-22 Baylor Res Inst Anti-cd40 antibodies and uses thereof
JP2013504599A (ja) * 2009-09-14 2013-02-07 ベイラー リサーチ インスティテュート ランゲルハンス細胞に向けられたワクチン
JP5628544B2 (ja) * 2010-04-07 2014-11-19 株式会社豊田中央研究所 クロストリジウム・サーモセラム由来のタンパク質複合体を構築するためのタンパク質及びその利用
MX2012012833A (es) 2010-05-07 2012-11-30 Baylor Res Inst Cebado cruzado de celulas t cd8 positivas humanos moderada por inmunoreceptores de celulas dendriticas (dcir).
BR112013002940A2 (pt) * 2010-08-13 2019-09-24 Baylor Res Institute adjuvantes de nova vacina baseados no direcionamento dos adjuvantes para os anticorpos diretamente às células que apresentam antígenos
US20120128710A1 (en) * 2010-11-02 2012-05-24 Baylor Research Institute Enhancement of Pathogen-Specific Memory Th17 Cell Responses
TW201247706A (en) * 2011-03-08 2012-12-01 Baylor Res Inst Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
CA2831294A1 (en) * 2011-03-25 2012-10-04 Baylor Research Institute Compositions and methods to immunize against hepatitis c virus
CN113461819B (zh) 2011-04-29 2024-01-02 埃派斯进有限公司 抗-cd40抗体及其使用方法
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
WO2014031984A1 (en) * 2012-08-24 2014-02-27 Baylor Research Institute Immunological detection methods and compositions
CA2884430A1 (en) * 2012-09-07 2014-03-13 Baylor Research Institute Hiv vaccine compositions and methods
AU2013337903B2 (en) 2012-10-30 2018-08-16 Apexigen, Inc. Anti-CD40 antibodies and methods of use
CA2916694C (en) 2013-06-28 2023-01-17 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
JP7037884B2 (ja) 2014-01-13 2022-03-17 ベイラー リサーチ インスティテュート Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
PT3166607T (pt) 2014-07-11 2022-12-07 Gilead Sciences Inc Moduladores de receptores de tipo toll para o tratamento do vih
CN105821030A (zh) * 2015-01-04 2016-08-03 彭霞 表达α1，3半乳糖转移酶的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法
CN105821029A (zh) * 2015-01-04 2016-08-03 彭霞 异源融合基因修饰的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法
US20180356398A1 (en) 2017-06-09 2018-12-13 Fujifilm Corporation Living tissue model device, vascular wall model, vascular wall model device and method of evaluating test substance
CN110997903B (zh) 2017-08-10 2024-03-29 古德T细胞有限公司 用于癌症治疗的t细胞的活化方法
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
CN112638375A (zh) 2018-06-15 2021-04-09 旗舰创业创新五公司 通过后细胞信号传导因子的调节来增加免疫活性
EP3922642A4 (en) 2019-02-08 2023-03-29 Good T Cells, Inc. METHOD OF ACTIVATING T LYMPHOCYTES FOR THE TREATMENT OF CANCER
EP3947454A1 (en) 2019-03-27 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant proteins with cd40 activating properties
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
CA3161633A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines
JP2023502712A (ja) * 2019-11-21 2023-01-25 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 抗ｐｄ－１／ｉｌ－１５免疫サイトカインによる新しいｐｄ－１標的免疫療法
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
WO2021239838A2 (en) 2020-05-26 2021-12-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
JP2023532339A (ja) 2020-06-29 2023-07-27 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
CA3200878A1 (en) 2020-11-12 2022-05-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes
GB202019879D0 (en) * 2020-12-16 2021-01-27 Ucl Business Ltd Polypeptide
EP4267176A1 (en) 2020-12-23 2023-11-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells
CA3209251A1 (en) 2021-01-29 2022-08-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
US20240316104A1 (en) 2021-06-29 2024-09-26 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
KR20240103030A (ko) 2021-11-17 2024-07-03 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 범용 사르베코바이러스 백신
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024074571A1 (en) 2022-10-05 2024-04-11 Institut National de la Santé et de la Recherche Médicale Dc-targeting vaccine against nipah virus infection
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) * 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3949064A (en) 1973-10-26 1976-04-06 Baxter Laboratories, Inc. Method of detecting antigens or antibodies
US4174384A (en) 1975-06-30 1979-11-13 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
DK8189A (da) 1988-01-12 1989-07-13 Bunge Australia Antigen-antistof-konjugater, deres fremstilling og anvendelse
US6054312A (en) * 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
WO1999057155A1 (en) 1998-05-01 1999-11-11 The Procter & Gamble Company Laundry detergent and/or fabric care compositions comprising a modified antimicrobial protein
WO2000000156A2 (en) * 1998-06-26 2000-01-06 Trustees Of Dartmouth College Methods for modulating immunological responses by targeting antigen to apcs in conjuction with anti-cd40 ligands
JP2000157282A (ja) * 1998-11-30 2000-06-13 Toyota Central Res & Dev Lab Inc 酵素配列複合体及び固定化酵素配列複合体とそれらの製造方法、担体分子及び酵素
CA2399028A1 (en) * 2000-03-23 2001-09-27 Akzo Nobel N.V. Use of mia in immunotherapy
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
AU2002305452A1 (en) * 2001-05-08 2002-11-18 Emory University Regulating immine responses using dendritic cells
GB0118367D0 (en) 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
RU2312896C2 (ru) * 2001-09-20 2007-12-20 Глаксо Груп Лимитед Последовательность нуклеиновой кислоты, кодирующая белок gag вич-1, способ получения указанной последовательности, вектор, содержащий ее, белок, кодируемый ею, фармацевтическая композиция и их применение для профилактики и/или лечения вич-инфекции и спида
US20050106700A1 (en) * 2001-10-11 2005-05-19 Tsuyoshi Nomura Method of purifying recombinant fused protein and method of producing protein using the same
WO2003046012A1 (en) * 2001-11-30 2003-06-05 Crucell Holland B.V. Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation
EP2258712A3 (en) * 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
JP2004236504A (ja) * 2003-02-03 2004-08-26 Toyota Central Res & Dev Lab Inc 酵素配列複合体及び固定化酵素配列複合体とそれらの製造方法、担体分子及び酵素
JP2005143444A (ja) * 2003-11-19 2005-06-09 Lion Corp キメラ酵素及び洗浄剤組成物
WO2006014729A2 (en) * 2004-07-20 2006-02-09 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
US20080063656A1 (en) 2004-08-09 2008-03-13 Emini Emilio A Adenoviral Vector Compositions
SG159555A1 (en) * 2004-11-16 2010-03-30 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
EP1752533A1 (en) * 2005-08-12 2007-02-14 Institut National de la Recherche Agronomique Fusion proteins between plant cell-wall degrading enzymes, and their uses
WO2007103048A2 (en) * 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
CA2730742C (en) 2008-07-16 2017-05-23 Baylor Research Institute Hiv vaccine based on targeting maximized gag and nef to dendritic cells

Similar Documents

Publication Publication Date Title
JP2015071598A5 (https=)
RU2011105119A (ru) Вич вакцина, основанная на направленности максимизированных gag и nef на дендритные клетки
Idoyaga et al. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A
Birkholz et al. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II–restricted antigen presentation
Trumpfheller et al. The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine
TW201200150A (en) Dendritic cell immunoreceptors (DCIR)-mediated crosspriming of human CD8+ T cells
CN101679508B (zh) 基于靶向抗原至抗原呈递细胞上表达的dcir的疫苗
AU2010291939B2 (en) Vaccines directed to Langerhans cells
JP2010518024A5 (https=)
US20250388636A1 (en) T-cell expansion method and uses
US9885017B2 (en) Compositions and methods to immunize against hepatitis C virus
Epaulard et al. Macrophage-and neutrophil-derived TNF-α instructs skin langerhans cells to prime antiviral immune responses
TW201305193A (zh) 靶向結核病（ｔｂ）疫苗之樹突細胞（ｄｃ）
US20120121592A1 (en) Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells
WO2012122396A1 (en) Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
TW201100096A (en) Antigen presenting cell targeted anti-viral vaccines
JP2013535508A (ja) 抗体付きアジュバントを抗原提示細胞に直接的に標的化することをベースにした新規ワクチンアジュバント
JP2013535508A5 (https=)
Apostolico et al. Dendritic cell targeting effectively boosts T cell responses elicited by an HIV multiepitope DNA vaccine
WO2013009841A1 (en) Subsets of antigen-presenting cells (apc's) in the human vagina and their distinct functions
You et al. Priming of Autoreactive CD8+ T Cells Is Inhibited by Immunogenic Peptides Which Are Competitive for Major Histocompatibility Complex Class I Binding
Brody et al. Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant
JPWO2021239838A5 (https=)
US10226518B2 (en) Ubiquitinylated proteins
Lim et al. A GD Type of Cancel Culture